On Wednesday, Bayer AG BAYRY reported fourth-quarter 2024 adjusted EPS of $0.28, lacking the consensus of $1.00.
The corporate reported core earnings per share of 1.05 euros, down from 1.85 euros a yr in the past.
The crop science and drug firm reported gross sales of $12.52 billion (11.73 billion euros), beating the consensus of $11.30 billion.
For the fourth quarter, Bayer reported a 22% fall in adjusted EBITDA to 2.35 billion euros.
CEO Invoice Anderson called 2025 a “pivotal yr” for the corporate. “It’s the second yr in Bayer’s turnaround and would be the most tough by way of monetary efficiency, with internet gross sales roughly according to, and earnings and free money circulate behind the prior yr. The corporate expects improved efficiency from 2026 onwards,” he mentioned.
The Bayer Group achieved its adjusted steering for 2024. “We have now three nice companies with enticing long-term prospects,” Anderson mentioned on the Monetary Information Convention on Wednesday. “Nonetheless, to get to the alternatives forward, we first must steer via what’s going to proceed to be difficult instances,”
Bayer’s Crop Science division goals to enhance profitability via key measures in product improvement, analysis, manufacturing and gross sales. By 2029, the division expects so as to add over €1 billion in annual earnings. The plan additionally features a broad cost-saving initiative.
Bayer expects the division to develop sooner than the market, with innovation contributing greater than €3.5 billion in extra gross sales by 2029. By then, it goals for an EBITDA margin within the mid-20% vary, excluding particular gadgets.
The German conglomerate forecasts 2025 adjusted EBITDA of between 9.3 billion and 9.8 billion euros and core earnings per share of 4.25 to 4.75 euros.
The corporate’s operational belt-tightening efforts generated 500 million euros in financial savings in 2024 and is anticipated to ship one other 800 million euros this yr.
Bayer mentioned the pharma division ought to return to progress in 2027 and increase margins starting in 2028, with gross sales of Nubeqa and Kerendia anticipated to achieve a mixed 2.5 billion euros in 2025.
Value Motion: BAYRY inventory is up 6.13% at $6.58 on the final examine Wednesday
Additionally Learn:
Picture: Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
